论文部分内容阅读
目的:探讨依那普利联合生脉注射液治疗心源性休克的临床疗效。方法:选择2009年1月到2010年12月在我院住院的48例心源性休克患者,随机分为两组,研究组23例患者,对照组25例患者,对照组采用生脉注射液治疗,研究组在对照组治疗基础上加用依那普利,治疗12 h后观察两组病例血压、心率、血氧饱和度、尿量、肌酸激酶同工酶(CKMB)、血清肌钙蛋白I(CTn I)、血管紧张素Ⅱ(AngⅡ)水平、评价48 h后患者的死亡率。结果:治疗12 h后,与治疗前比较。两组各项指标血压上升明显、心率下降显著、血氧饱和度升高明显、尿量明显增加,差异显著,有统计学意义(P<0.05)。研究组与对照组比较,研究组血压上升明显、心率下降显著、血氧饱和度升高明显、尿量明显增加,CTn I,AngⅡ,CKMB水平均下降,差异显著,有统计学意义(P<0.05),治疗48 h后,对照组死亡患者6例,死亡率(24%),研究组死亡率死亡患者1例(4.3%),两组比较,差异显著,有统计学意义(P<0.05)。结论:依那普利联合注射用生脉治疗心源性休克临床疗效较好,值得临床推广应用。
Objective: To investigate the clinical efficacy of enalaprol combined with Shengmai injection in the treatment of cardiogenic shock. Methods: Forty-eight patients with cardiogenic shock admitted to our hospital from January 2009 to December 2010 were randomly divided into two groups: 23 patients in the study group and 25 patients in the control group. The control group received Shengmai injection The study group was given enalapril on the basis of the control group, and the blood pressure, heart rate, blood oxygen saturation, urine output, creatine kinase (CKMB), serum muscle calcium Protein I (CTn I) and angiotensin II (AngⅡ) were measured to evaluate the mortality of patients after 48 h. Results: After 12 hours of treatment, compared with before treatment. Blood pressure increased significantly in both groups, with significant decrease of heart rate, significant increase of oxygen saturation and significant increase of urine output with significant difference (P <0.05). The study group compared with the control group, the study group increased blood pressure significantly, heart rate decreased significantly, oxygen saturation increased significantly, urine output increased significantly, CTn I, Ang ¢ ò, CKMB levels were significantly lower, with significant difference (P < 0.05). After 48 hours of treatment, 6 patients died in the control group (24%) and 1 patient died in the study group (4.3%). There was significant difference between the two groups (P <0.05 ). Conclusion: Enalapril combined with Shengmai injection in the treatment of cardiogenic shock clinical efficacy is good, worthy of clinical application.